What’s the current market cap for Bavarian Nordic A/S stock?

Bavarian Nordic A/S (BAVA) has a market cap of €1.8bn as of June 20, 2026.

What is the P/E ratio for Bavarian Nordic A/S stock?

The price to earnings (P/E) ratio for Bavarian Nordic A/S (BAVA) stock is 11.76 as of June 20, 2026.

Does Bavarian Nordic A/S stock pay dividends?

No, Bavarian Nordic A/S (BAVA) stock does not pay dividends to its shareholders as of June 20, 2026.

When is the next Bavarian Nordic A/S dividend payment date?

Bavarian Nordic A/S (BAVA) stock does not pay dividends to its shareholders.

What is the beta indicator for Bavarian Nordic A/S?

Bavarian Nordic A/S (BAVA) has a beta rating of 0.95. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Bavarian Nordic A/S stock | €BAVA Share Price

About Bavarian Nordic A/S

Bavarian Nordic A/S is a biotechnology company based in Denmark, primarily focused on the development, manufacture, and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company's product portfolio includes vaccines for smallpox, Ebola, and other infectious diseases, with its most notable products being the smallpox and monkeypox vaccine, Jynneos (also known as Imvanex or Imvamune). Founded in 1994, Bavarian Nordic has established partnerships with several government agencies, enhancing its strategic positioning in the vaccine development sector. The company operates globally, with its headquarters located in Kvistgaard, Denmark, and manufacturing facilities in various locations supporting its international distribution efforts. Bavarian Nordic leverages proprietary vaccine platform technologies such as MVA-BN, contributing to its competitive advantage in the biotechnology industry.

Ticker

€BAVA

Sector

Health

Primary listing

XGAT

Employees

1,861

Headquarters

Hellerup, Denmark

Website

www.bavarian-nordic.com

BAVA Metrics

BasicAdvanced

€1.8bn

11.76

€1.98

0.95

-

Bulls say / Bears say

Bavarian Nordic raised its full-year 2026 revenue guidance to DKK 5.5–5.7 billion and lifted its EBITDA margin forecast to ~28 % after securing an additional $97 million option from the U.S. Department of Health and Human Services for supply of a freeze-dried Jynneos smallpox vaccine (Reuters).

The U.S. FDA’s March 2025 approval of Bavarian Nordic’s freeze-dried formulation of its mpox and smallpox vaccine enhances shelf life and stability for stockpiling, bolstering its strategic positioning in government preparedness programs (Reuters).

The Travel Health segment delivered 24 % revenue growth YOY in H1 2025, driven by rabies and tick-borne encephalitis vaccines, diversifying its revenue base and strengthening cash flows beyond public-preparedness products (Reuters).

Chief Executive Paul Chaplin announced he will step down at year-end, marking the second major leadership shake-up since shareholders torpedoed a €3 billion takeover bid, creating potential disruption to strategic execution and continuity (Bloomberg).

Shares plunged 6.4 % to their lowest level since July after Bavarian Nordic narrowed its 2025 revenue outlook to DKK 6 billion (the low end of its prior DKK 6–6.6 billion guidance), signalling limited near-term contract visibility and heightened execution risk (Reuters).

First-quarter 2026 revenue missed consensus at DKK 1.06 billion versus DKK 1.13 billion expected, as Public Preparedness sales fell 53 % YOY to DKK 294 million, underscoring normalization risks in its high-margin government business (Reuters via Investing.com).

Data summarised monthly by Lightyear AI. Last updated on 24 May 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Market data provided by CBOE Europe and Deutsche Börse.

About Bavarian Nordic A/S

Ticker

Primary listing

Employees

Headquarters

BAVA Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy €BAVA

Lightyear

Legal

Work with us

Bulls say / Bears say

Bavarian Nordic A/S/€BAVA

About Bavarian Nordic A/S

Ticker

Primary listing

Employees

Headquarters

BAVA Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

What’s the current market cap for Bavarian Nordic A/S stock?

What is the P/E ratio for Bavarian Nordic A/S stock?

Does Bavarian Nordic A/S stock pay dividends?

When is the next Bavarian Nordic A/S dividend payment date?

What is the beta indicator for Bavarian Nordic A/S?

Bulls say / Bears say